Ulisse Biomed S.p.A. (BIT:UBM)

Italy flag Italy · Delayed Price · Currency is EUR
0.7500
-0.0200 (-2.60%)
Apr 25, 2025, 5:35 PM CET
-40.94%
Market Cap 18.36M
Revenue (ttm) 767.93K
Net Income (ttm) -5.94M
Shares Out 24.48M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,000
Average Volume 18,950
Open 0.7500
Previous Close 0.7700
Day's Range 0.7500 - 0.7500
52-Week Range 0.6800 - 1.3400
Beta 0.70
RSI 46.66
Earnings Date Jun 27, 2025

About Ulisse Biomed

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 10
Stock Exchange Borsa Italiana
Ticker Symbol UBM
Full Company Profile

Financial Performance

In 2024, Ulisse Biomed's revenue was 767,929, an increase of 1059.87% compared to the previous year's 66,208. Losses were -5.94 million, 23.8% more than in 2023.

Financial Statements

News

There is no news available yet.